Table 2 FDA-registered clinical trials of 89Zr-labeled immune-targeted PET for cancer applications
ClinicalTrials.gov ID | Target | Phase | Treatment | Sponsor |
|---|---|---|---|---|
NCT02453984 | PD-L1 | Not Applicable | ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors Prior to and During MPDL3280A Treatment | University Medical Center Groningen |
NCT03514719 | PD-L1 | Phase 1 | PD-L1 Imaging in Non Small Cell Lung Cancer’ (PINNACLE) | Radboud University Medical Center |
NCT04006522 | PD-L1 | Phase 2 | An Exploratory Study of 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | University of Texas Southwestern Medical Center |
NCT04977128 | PD-L1 | Not Applicable | Safety Study of 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors | Wuxi No. 4 People’s Hospital |
NCT03638804 | PD-L1 | Not Applicable | 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 positive Advanced Solid Tumors | The First Affiliated Hospital of Soochow University |
NCT05742269 | PD-L1 | Not Applicable | Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab to Monitor Immune Responses in Metastatic Triple Negative Breast Cancer | Karolinska University Hospital |
NCT03850028 | PD-L1 | Not Applicable | Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma | University Medical Center Groningen |
NCT05404048 | PD-L1 | Phase 2 | Programmed Death Ligand 1 (PD-L1)-PET Imaging in Patients With (Diffuse) Large B-cell Lymphoma Who Are Treated With CD19-directed CAR T-cell Therapy: a Pilot Study | University Medical Center Groningen |
NCT05638334 | PD-L1 x 4-1BB | Phase 1 | An Open Label, Multicentre, Positron Emission Tomography (PET) Imaging Study Using Zirconium-89 to Investigate the Biodistribution and Tumour Uptake of a PD-L1 × 4-1BB Bispecific Antibody (S095012) in Patients With Advanced Solid Tumours | Institut de Recherches Internationales Servier |
NCT02760225 | PD-1 | Not Applicable | 89Zr-pembrolizumab-PET Imaging in Patients With Locally Advanced or Metastatic Melanoma or Non-small Cell Lung Cancer | University Medical Center Groningen |
NCT03065764 | PD-1 | Phase 2 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | Amsterdam UMC, location VUmc |
NCT05068102 | PD-1 and SIRPα | Phase 1 | An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab | Boehringer Ingelheim |
NCT04706715 | LAG-3 | Phase 1Phase 2 | ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Patients With Advanced Solid Cancer Prior to and During Treatment With Cemiplimab With or Without Platinum-based Chemotherapy | University Medical Center Groningen |
NCT04566978 | LAG-3 | Early Phase 1 | A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients With Relapsed/Refractory DLBCL | Memorial Sloan Kettering Cancer Center |
NCT03313323 | CTLA-4 | Phase 2 | Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma | Amsterdam UMC, location VUmc |
NCT04029181 | CD8 | Phase 1 Phase 2 | ImmunoPET Imaging With ZED88082A in Patients Before and During Treatment With 1) MPDL3280A or 2) PD-1 Antibody Plus or Minus Ipilimumab | University Medical Center Groningen |
NCT05259709 | CD8 | Phase 1 | A First-in-Human Study of 89Zr-DFO-REGN5054 (Anti-CD8) Positron Emission Tomography in Patients With Solid Malignancies Treated With Cemiplimab | Regeneron Pharmaceuticals |
NCT05371132 | CD8 | Phase 1 | Pilot Phase I Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | City of Hope Medical Center |
NCT05289193 | CD8 | Phase 2 | CD8 + Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial) | Memorial Sloan Kettering Cancer Center |
NCT05013099 | CD8 | Phase 2 | A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies, Scheduled to Receive Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy | ImaginAb, Inc |
NCT03853187 | CD8 | Phase 2 | Imaging Tumor-infiltrating CD8 + T-cells in Non-small Cell Lung Cancer Upon Neo-adjuvant Treatment With Durvalumab (MEDI4736) | Radboud University Medical Center |
NCT04955262 | CD8 | Phase 1 | A Phase 1b, Open Label, Multicenter Study of Positron Emission Tomography With Computed Tomography (PET/CT) Using 89Zr Df-IAB22M2C (CD8 PET/CT Tracer) in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | Nektar Therapeutics |
NCT03533283 | CD8 | Phase 1 Phase 2 | An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma | Hoffmann-La Roche |
NCT02760199 | CD3 | Phase 1 | 89Zr-AMG211 PET Imaging in Patients With Relapsed/Refractory Gastrointestinal Adenocarcinoma Before and During Treatment With AMG 211 | University Medical Center Groningen |